DHTKD1 and neoplasm: The intravenous administration of the nanomedicine resulted in a significant reduction in tumor size and pulmonary metastasis in prostate cancer-bearing mice, whereby a 1000-fold less virus was needed when compared to Ad[I/PPT-E1A] alone [98].